Search Results
78 Results Found for “Acromegaly”
Peripheral neuropathy is a common and clinically heterogeneous condition resulting from damage to the peripheral nervous system, affecting sensory, motor and autonomic fibers.1 Its diagnostic complexity stems from a broad spectrum of etiologies, including metabolic, autoimmune, infectious, toxic, neoplastic and ...
The European Society of Endocrinology (ESE) has announced the 2026 ESE Award winners, recognizing leading contributors to scientific progress and clinical innovation in endocrinology. All recipients will present plenary lectures at the European Congress of Endocrinology (ECE) 2026, to be held in Prague, Czech Republic, 9–12 May.
In this Future Leader Q&A, Dr Pedro Marques shares insights from his pioneering work in pituitary tumour endocrinology, highlighting the impact of mentorship, international collaboration and advances shaping the future of personalized endocrine care.
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...
Acromegaly is a chronic disease caused by an excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).1,2Â Besides facial and acral changes, systemic complications lead to decreased quality of life and survival rates.3Â The primary goal of acromegaly treatment ...
Acromegaly is the clinical consequence of chronic excessive exposure of the tissues to growth hormone (GH) and its second messenger, insulin-like growth factor-I (IGF-I). The excess GH secretion is almost exclusively secondary to a GH-secreting pituitary adenoma (somatotropinomas); however, excess ...
Extended-release formulations of the somatostatin analogues, octreotide and lanreotide, are first-line medical therapies for patients with acromegaly who have contraindications for, or are not cured by, surgical intervention and/or radiotherapy. touchENDOCRINOLOGY are joined by Dr Diego Ferone (University of ...
Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. It occurs when the pituitary gland produces too much growth hormone (GH). touchENDOCRINOLOGY were delighted to speak with Prof. Thierry Brue (Aix-Marseille University, Marseille, France) about the current treatment ...
Clinicians depend on accurate, precise and reproducible hormone measurements for the diagnosis and management of endocrine disorders. Immunoassays have constituted one of the major methods of measuring hormone levels in blood, urine and other fluids, as well as in tissue ...
We were delighted to catch up with Dr Susan Samson (Mayo Clinic, Jacksonville, FL, US) to discuss the one-year outcomes of oral octreotide capsule use in patients with acromegaly. 'One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 ...
Acromegaly is a chronic, progressive disease characterized by an excess secretion of growth hormone, and consequently, increased circulating insulin-like growth factor 1 (IGF-1) levels. These patients typically exhibit acral and soft tissue overgrowth, headache, arthritis and visual disturbances. Impaired glucose tolerance ...
Welcome to the latest issue of the newly-renamed touchREVIEWS in Endocrinology, previously European Endocrinology. The decision to rename and widen the reach of the journal has been taken after a great year for touchENDOCRINOLOGY, and we feel that in an ...
McCune–Albright syndrome (MAS) is a genetic disorder first described by McCune1 and Albright2 in the 1930s as a triad of polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty (Figure 1). Since then, other hyperfunctioning endocrinopathies have been described in ...
Welcome to the summer edition of US Endocrinology. In this issue we present authoritative, up-to-date information on a wide range of salient topics. The pandemic of obesity is driving the diabetes epidemic across the globe, with developing countries especially bearing ...
The pituitary gland, or hypophysis, is the ‘master gland’ that secretes multiple hormones which regulate the functioning of other endocrine organs, such as the thyroid, adrenal cortex and gonads. Though none of the major pituitary hormones directly control the endocrine ...
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant endocrine tumour syndrome characterised by three main manifestations which are primary hyperparathyroidism (78–94%), gastroenteropancreatic neuroendocrine tumours (GEP-NETs) (35–78%) and pituitary adenomas (20–65%).1 As described, GEP-NETs are the second most common component of MEN1 syndrome ...
Pituitary adenomas are benign tumours that arise from the adenohypophysis. They are the second most frequent intracranial tumour type after meningiomas, and account for 16.2% of all primary cranial neoplasms.1 Though likely an underestimate, the incidence of pituitary adenomas is approximately ...
Welcome to the latest edition of European Endocrinology, which features a range of articles describing current practices and research that directly affect endocrinologists, as well as being of interest to the wider biomedical community. Diabetes is the focus of ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
